Welcome to the Metabolon Blog!

We post commentary on all things metabolomics – from the latest publications to precision medicine. There are many exciting and growing metabolomics applications, so you never know what will inspire us to start writing.

New Hope for Patients with Inborn Errors of Metabolism and Rare Diseases

May 12, 2020, 1:00 PM
Sometimes, there is no playbook. That’s often the case with inborn errors of metabolism (IEM), defined as rare genetic disorders that cause alterations or deficiencies in enzymes involved in metabolism, and other rare diseases. A patient may exhibit clinical signs that don’t map to specific disorders, or a screening panel may come back with no clues. In these frustrating situations, clinical researchers – and patients – need more places to turn for answers.
Read more >

Stool Sample Collection: A Bottleneck to Gut Microbiome Research

May 4, 2020, 8:30 AM
Our gut microbiota is rich with biological insights, which can help clinical investigators better understand factors that influence both sickness and health. But despite its huge importance, this area of research is plagued by challenges. Stool samples from a diverse patient set are needed for researchers to gather valuable insights. Yet, collection, storage, and shipping issues constrain the quantity and quality of testable material. A new approach is needed to help researchers more fully explore the clues that live in the intestinal microbiota.
Read more >

Delivering Clinical Insights with Targeted Biomarker Assays

Apr 28, 2020, 1:32 PM
Metabolomics reveals biological insights otherwise unseen, making it a crucial component of drug development. For a successful metabolomics study, both small molecule discovery and the ability to dig deeper into specific biomarkers of interest are needed to uncover actionable insights that propel new therapeutic developments. A specific combination of technology and expertise is required to identify these biomarkers of interest and develop assays that are sensitive enough to explore them fully.
Read more >

Front lines of COVID-19

Apr 16, 2020, 10:50 AM
Metabolon scientists are collaborating with researchers on world-leading programs to use multi-omic deep phenotyping technologies, including metabolomics, to advance human health. A primary focus right now is on improving our collective understanding of the SARS-CoV-2 virus and the COVID-19 disease during this unprecedented pandemic.
Read more >

Achieve Study Success with Metabolon’s New Sample Handling Kit: Designed with Experience

Mar 31, 2020, 8:32 AM
Laboratory research studies require a huge commitment of time, money and resources. To help ensure the investment pays off in the form of key insights, simple precautions such as good sample collection practices should be utilized.
Read more >

Metabolomics Reveals Connection Between Gut Microbiome and Blood

Feb 25, 2020, 9:00 AM
Alpha diversity in the gut microbiome holds many clues to understanding human health. Now those clues are more accessible because Institute for Systems Biology (ISB) researchers can predict the diversity of an individual's gut microbiome by examining metabolites in the blood.
Read more >

Metabolon: A Rich Past and A Promising Future

Feb 10, 2020, 4:00 PM
When Annie Evans, Ph.D., first joined Metabolon, she had no idea of the breakthroughs she would be a part of, and how metabolomics would grow into an important ‘omics technology.
Read more >

Metabolon reveals a new ally for drug research and development programs: Picking program winners and demonstrating their value

Dec 16, 2019, 12:23 PM
Today’s biopharma companies are faced with extreme competition to secure support from investors, approval from regulators and buy-in from payers. How can a company and its new molecule shine above the noise to overcome these challenges? Enter metabolomics, the study of metabolites, the small-molecule end products of metabolism collectively known as the metabolome.
Read more >

Tier 1 Metabolite Identifications: A Compass to Rich Research Insights

Dec 11, 2019, 10:53 AM
Research is like a treasure hunt. Without the right navigation tools, precious time is spent on trial and error exploration to find the right path, increasing the cost as well as the risk of program failure. Metabolomics provides uniquely valuable guidance for navigating a biological system, but the signal-to-noise ratio from vast amounts of data can cloud your ability to see the actionable insight.
Read more >

The 4Cs of Metabolomics

Dec 4, 2019, 12:02 PM
Metabolon provides unmatched depth and breadth of metabolomics insights because no other organization has the 4 essential capabilities upon which truly insight-deriving metabolomics depends: Coverage, Competency, Comparability and Capacity.
Read more >

Metabolomics Brings New Insights to Type 2 Diabetes Research

Nov 18, 2019, 9:03 AM
Metabolon scientists are hard at work searching for new insights to aid in understanding mechanisms contributing to the development of Type 2 diabetes (T2D) .
Read more >

Adding Metabolomics to Genomics to tackle challenges in Lung Cancer

Nov 13, 2019, 7:15 AM
The field of lung cancer research has experienced many breakthroughs in recent years, particularly in precision medicine where oncologists can match genetic mutations to targeted therapies. However, many perplexing questions remain. Why does cancer impact some people and not others? Why do some people respond well to treatments and others don’t? For all the progress, we still have a long way to go.
Read more >

Microbiome Metabolism Reveals Mysteries of Diet’s Link to Epilepsy

Nov 6, 2019, 6:09 AM
Human health is complex, and the influence each internal system has on another can be quite extensive. Take epilepsy, for instance. It is well-established that a low-carbohydrate, high-fat ketogenic diet (KD) can help treat refractory epilepsy, which affects more than a third of epileptic patients who don’t respond to existing anticonvulsive drugs. What scientists haven’t understood until recently is how this kind of diet translates to brain activity. Turns out the answer lies in the gut microbiome.
Read more >

An interview with the Founder and CEO of Siolta

Oct 21, 2019, 10:05 AM
We sat down for a conversation with Nikole Kimes, Ph.D., Co-Founder and CEO of Siolta. The company’s name, which is pronounced sheel-ta, is a Gaelic word for “seeds” and speaks to the company’s microbial therapeutics that are created to reseed the depleted gut microbiome with naturally occurring bacteria, which are essential for a healthy immune system.
Read more >

Small Molecules at the Intersection of Health and Microbiota

Oct 4, 2019, 11:24 AM
Metabolon Senior Study Director, Karen DeBalsi, Ph.D., will speak at the 5th Annual European Microbiome Congress. Her seminar titled, “Small Molecules at the Intersection of Health and Microbiota,” will explore how Metabolon’s approach to metabolomics can assess efficacy, monitor toxicity, provide discover biomarkers, measure therapeutic response, determine optimal dosing, gauge non-compliance, and segregate responders from non-responders. The following Q&A from Kiasko Research provides a preview of her upcoming presentation.
Read more >